Ivosidenib NEW
| Price | $66 | $123 | $196 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Ivosidenib | CAS No.: 1448347-49-6 |
| Purity: 99.7% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Ivosidenib |
| Description | Ivosidenib (AG-120) is an orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1) with potential antineoplastic activity. It specifically inhibits a mutated form of IDH1 in the cytoplasm, preventing the formation of the oncometabolite 2-hydroxyglutarate (2 hG), which may induce cellular differentiation and inhibit cellular proliferation in IDH1-expressing tumor cells. |
| Cell Research | TF-1 cells or primary human AML patient samples expressing mutant IDH1 are treated with AG-120. (Only for Reference) |
| In vitro | TF-1 cells or primary human AML patient samples expressing mutant IDH1 are treated with AG-120.Treatment with AG-120 decreases intracellular 2-HG levels, inhibites growth factor independent proliferation and restores erythropoietin (EPO)-induced differentiation in TF-1 IDH1-R132H cells. Similarly, pharmacological inhibition of mutant IDH1 enzyme with AG-120 in primary human blast cells cultured ex vivo provides an effective way to lower intracellular 2-HG levels and induces myeloid differentiation[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | Ethanol : 100 mg/mL (171.54 mM) H2O : < 1 mg/mL (insoluble or slightly soluble) DMSO : 50 mg/mL (85.77 mM) |
| Keywords | Ivosidenib | inhibit | AG 120 | Inhibitor | AG120 | Isocitrate Dehydrogenase (IDH) |
| Inhibitors Related | Rotenone | Mycophenolate Mofetil | Isomalt |
| Related Compound Libraries | Bioactive Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $82.00/2mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
| $0.00/1g |
VIP4Y
|
Wuhan Nutra Biotechnology Co.,Ltd
|
2021-05-24 | |
| $0.00/1kg |
VIP3Y
|
Henan Aochuang Chemical Co.,Ltd.
|
2022-10-09 | |
| $1.00/1g |
VIP5Y
|
Career Henan Chemical Co
|
2019-12-20 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hills
INQUIRY